Randomized Safety Study of CVT-301 Compared to an Observational Control Group

A randomized, double-blind, placebo-controlled, Phase 2b study in patients with PD
(CVT-301-003) demonstrated clinically important, and statistically significant
CVT-301-associated improvements in motor function at doses of 35 and 50 mg LD FPD, compared
with placebo, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor
assessment (Part 3); furthermore, CVT-301 was generally safe and well tolerated. A Phase 3,
randomized, placebo-controlled study designed to assess the efficacy and safety of 35 mg and
50 mg FPD as an adjunct to a CD/LD regimen in the treatment of OFF symptoms over 12 weeks
(CVT-301-004) was conducted in parallel with this study.

Inclusion Criteria:

- Has signed and dated an Internal Review Board/Independent Ethics Committee
(IRB/IEC)-approved informed consent form before any protocol-specific screening
procedures are performed.

- Women of child-bearing potential must use protocol-defined contraceptive measures and
must have a negative serum human chorionic gonadotropin (hCG) test at screening. These
patients must be willing to remain on their current form of contraception for the
duration of the study.

- Patients who have idiopathic PD (i.e., not induced by drugs or other diseases) as
defined by fulfilling Steps 1 and 2 of the United Kingdom (UK) Brain Bank criteria,
diagnosed after the age of 30 years.

- Patients who are classified as Stage 1 to 3 (in the ON state) on the modified Hoehn
and Yahr scale for staging of PD severity.

- Patients who have experienced motor fluctuations for a minimum of 2 hours of average
daily OFF time per waking day (excluding early morning OFF time) by self-report and
confirmed by the PD Diary (on 3 consecutive days) during the screening period.

Exclusion Criteria:

- Patients who have dyskinesia of a severity that would significantly interfere with
their ability to participate or perform study procedures.

- Pregnant or lactating females or females wishing to become pregnant.

- Patients who have any known contraindication to the use of levodopa (LD), including a
history of malignant melanoma or a history of narrow-angle glaucoma.

- Patients who have had previous surgery for PD (including but not limited to deep brain
stimulation [DBS] or cell transplantation).

- Patients with a history of psychotic symptoms requiring treatment, or suicide ideation
or attempt within the prior 12 months.